Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERICLES: pembrolizumab plus metronomic oral cyclophosphamide in chest wall breast cancer
2017-003343-37Phase 2Active
- Sponsor
- European Institute of Oncology
- Start
- Sep 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and cyclophosphamide in breast cancer and inflammatory breast cancer (IBC), sponsored by European Institute of Oncology. Primary endpoint: Objective response rate. Started Sep 2021; status: active.
02
Drugs
pembrolizumabcyclophosphamide
03
Conditions
breast cancerinflammatory breast cancer (IBC)
Beyond the preview
Go deeper on 2017-003343-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003343-37.